Clinical trial
Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chemotherapy
NCT02740894 is registered in ClinicalTrials.gov with Taipei Veterans General Hospital, Taiwan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chemotherapy
- Lead sponsor
- Taipei Veterans General Hospital, Taiwan
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 29, 2016
- Completion date
- April 30, 2016
- Enrollment
- 100 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
is targeted therapy increasing survival inoperable nonsmall cell lung cancer with spinal metastasis ?